Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning, ladies and gentlemen, and welcome to the Protalix ...
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...
FDA grants orphan drug designation to potential treatment of STXBP1 developmental and epileptic encephalopathy
Research that was carried out by Baylor College of Medicine and Texas Children's Hospital doctors has led to the U.S. Food ...
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its ...
PLX: Self-Sustaining Rise to Lead in Renal Rare Disease
PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2024 Financial and Operational Review Protalix Biotherapeutics, Inc.
obj18h
Finding its rhythm: Startup seeks $4M in funding for trailblazing atrial fibrillation treatment
A new Ottawa biotech startup is seeking to raise $4 million to produce groundbreaking treatments aimed at curing one of the ...
Codexis (CDXS) Receives a Hold from TD Cowen
TD Cowen analyst Brendan Smith maintained a Hold rating on Codexis (CDXS – Research Report) today and set a price target of $3.00. The ...
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
Detailed price information for Sonnet Biot Inc (SONN-Q) from The Globe and Mail including charting and trades.
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
Detailed price information for Sonnet Biotherapeutics Holdings Inc (SONN-Q) from The Globe and Mail including charting and trades.
Pharmabiz11h
Biopharma & medical devices cos view advanced infrastructure to propel manufacturing & new drug development
Biopharma & medical devices cos view advanced infrastructure to propel manufacturing & new drug development: Nandita Vijayasimha, Bengaluru Saturday, November 16, 2024, 08:00 Hrs ...
Future Market Insights21h
Animal Model Market to Reach USD 3,476.8 Million by 2034, Growing at a 6% CAGR
The global animal model market is expected to grow from USD 1,943.3 million in 2024 to USD 3,476.8 million by 2034, at a CAGR ...
Arbutus Biopharma Corporation: Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional ...